Mestastop is creating a cancer metastasis focussed platform, which uses wet lab biology and predictive analytics to identify and distinguish unique properties of metastasis and leverage them for drug discovery and patient treatment.
In 2021, the company had secured a seed funding of Rs 2 crore led by IIM Ahmedabad’s CIIE with participation from IKP and angel investors.
“Over the last three years, we have been involved in extensive R&D, which has created novel platforms. We are ready to leap forward and use these platforms for our discovery and diagnostics efforts. I thank all existing investors for supporting us and the incoming investors for sharing our vision and passion,” said co-founder
Arnab Roy Chowdhury in a statement.
The company said that the funds will be used to generate proof of concept data with small molecules around the identified first-in-class targets and also help progress drug repurposing efforts to delay metastasis by identifying probable clinical candidates.
Alok from 92 Angels said, “Mestastop is on a noble mission to defeat cancer, a dreaded disease that takes millions of lives every year. 92Angels, a group of investors whose specific goal is to support companies that make a better world, is privileged to be part of Mestastop’s journey.”
“We are pleased to back Arnab, Debabani and the team at Mestastop. The company’s vision of developing novel platforms and predictive diagnostics to solve for cancer metastasis resonates well with our thesis at Malpani Ventures to back purpose-driven tech-first founders in healthcare,” said Anirudh Malpani from Malpani Ventures
